Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03825315 · ClinicalTrials.gov registry record · Phase 2
DaxibotulinumtoxinA for Injection for the Treatment of Plantar Fasciitis
A Phase 2 study of Plantar Fasciitis, sponsored by Revance Therapeutics.
- Completed
- Registry status
- Phase 2
- Development phase
- 155
- Enrollment target
- 20
- Study locations
NCT03825315 is a Phase 2 study of Plantar Fasciitis that has completed, run by Revance Therapeutics. The registered enrollment target is 155 participants, above the 83-participant average among 6 other Plantar Fasciitis trials with a reported enrollment target (87% higher). The trial reports 20 study locations across 9 states.
The verdict
NCT03825315, a Phase 2 study of Plantar Fasciitis, has completed, sponsored by Revance Therapeutics.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 155 participants
- Enrollment target
- 20
- Study locations
Study Summary
This is a randomized, double-blind, placebo-controlled, parallel group, multi-center trial of a single administration of DaxibotulinumtoxinA (DAXI) (high-dose; low-dose) for injection versus placebo for the management of Plantar Fasciitis.
Conditions Studied
Interventions
- OTHER Placebo
- BIOLOGICAL DAXI 80 U
- BIOLOGICAL DAXI 120 U
Study Locations (20)
California
- Sacramento Foot and Ankle Center, Inc - Carmichael
- Bay Area Foot Care - Castro Valley
- West Coast Foot and Ankle - Huntington Beach
- Foot and Ankle Clinic - Los Angeles
- Bay Area Foot Care - San Francisco
- University Foot and Ankle Foundation - Santa Monica
Texas
- North Texas Institute of Neurology and Headache - Frisco
- Hermann Drive Research Hospital - Houston
- Futuro Clinical Trials, LLC - McAllen
- Strash Foot and Ankle Care - San Antonio
- The Podiatry Group of South Texas - San Antonio
Illinois
- Podiatry 1st - Belleville
- Rosalind Franklin University of Medicine & Science - North Chicago
Utah
- Rocky Mountain Foot and Ankle, LLC - Salt Lake City
- Wasatch Clinical Research - Salt Lake City
Arizona
- Aung Foot Health Clinic - Tucson
Florida
- LA Podiatry Group - West Palm Beach
Kansas
- Kansas Institute of Research - Overland Park
Nevada
- Advanced Foot & Ankle Center - Las Vegas
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 155 participants |
| Start Date | 2018-12-31 |
| Est. Completion | 2020-06-04 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03825315
The ClinicalTrials.gov registry entry for NCT03825315 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 155 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 83-participant average among 6 other Plantar Fasciitis trials with a reported enrollment target (87% higher). The listed sponsor is Revance Therapeutics, which has 27 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Plantar Fasciitis appearing as the primary indexed condition, and to 3 interventions - of which Placebo is the first listed.
NCT03825315 reports 20 study locations spanning 9 distinct geographic areas - top geographies include California, Texas, Illinois.
Frequently Asked Questions
What is clinical trial NCT03825315 about?
NCT03825315 is a clinical study titled "DaxibotulinumtoxinA for Injection for the Treatment of Plantar Fasciitis". This is a randomized, double-blind, placebo-controlled, parallel group, multi-center trial of a single administration of DaxibotulinumtoxinA (DAXI) (high-dose; low-dose) for injection versus placebo for the management of Plantar Fasciitis.
What is the current status of trial NCT03825315?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 155 participants. The study started on 2018-12-31. Estimated completion is 2020-06-04.
What conditions does trial NCT03825315 study?
This clinical trial studies the following conditions: Plantar Fasciitis.
What interventions are being tested in trial NCT03825315?
The interventions under investigation include: Placebo (OTHER), DAXI 80 U (BIOLOGICAL), DAXI 120 U (BIOLOGICAL).
Who is sponsoring clinical trial NCT03825315?
This trial is sponsored by Revance Therapeutics, which has 27 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03825315 being conducted?
This trial has 20 study locations across Arizona, California, Florida, Illinois, Kansas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Plantar Fasciitis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Phase 2 DaxibotulinumtoxinA for Injection for the Management of Plantar Fasciitis
COMPLETED · Phase 2
-
Lateral Plantar Artery Embolization For Plantar Fasciitis
RECRUITING · Phase 1
-
The Effects of Terrain Variation on Intrinsic Foot Musculature in Healthy Individuals and Individuals With Plantar Fasciitis
RECRUITING · NA
-
Treatment of Plantar Fasciitis With Dorsiflexion Night Splints and Medial Arch Supports
COMPLETED · Phase 4
-
Study of Effectiveness and Safety of Extracorporeal Shock Wave Therapy (ESWT) for Treatment of Painful Heel Syndrome
COMPLETED · Phase 3
-
Comparative Study of Amniotic Membrane Injectable in the Treatment of Recalcitrant Plantar Fasciitis
COMPLETED · NA
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.